Myriad Genetics to Acquire Precise Tumor, Precise Liquid : v

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...

Related Keywords

Utah , United States , Paulj Diaz , Glenn Farrell , Matt Scalo , Genetics Inc , Nasdaq , Exchange Commission , Intermountain Health System , Intermountain Precision Genomic , Tumor Test , Precise Liquid Test , Precise Tumor Test , Precise Tumor , Precise Liquid , Intermountain Healthcare , Solid Tumor , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Nasdaq Mygn , Myriad Genetics , Nc ,